| Description | KBU2046 is an orally administered compound that inhibits cell motility and invasion, effectively suppressing cancer metastasis and extending lifespan. This compound uniquely targets and binds to chaperone heterocomplexes, selectively modifying the interaction of client proteins involved in motility regulation, while avoiding the characteristics typical of classical HSP90 inhibitors. |
| molecular weight | 242.24 |
| Molecular formula | C15H11FO2 |
| CAS | 1143863-69-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 45 mg/mL (185.77 mM), Sonication is recommended. |
| References | 1. Xu L, et al. Precision therapeutic targeting of human cancer cell motility. Nat Commun. 2018 Jun 22;9(1):2454. |